Psychopharmacology

, Volume 178, Issue 2–3, pp 259–267

Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure

Original Investigation

Abstract

Rationale

Parametric preclinical studies of the benzodiazepine antagonist flumazenil have contributed to the understanding of the physical dependence associated with chronic benzodiazepine use. However, few parametric studies have been conducted in human participants.

Objective

This study was designed to assess the effect of duration of benzodiazepine exposure on the intensity of flumazenil-precipitated withdrawal in healthy volunteers.

Method

Participants were randomly assigned to receive either oral diazepam (15 mg/70 kg; n=10) or placebo (n=8) capsules nightly for 28 days. Effects of flumazenil (1 mg/70 kg, intravenously administered) were assessed in challenge sessions conducted before capsule ingestion, and after 1, 7, 14, and 28 days of capsule ingestion.

Results

Flumazenil produced a profile of participant-rated effects consistent with benzodiazepine withdrawal that peaked immediately after completion of the 5-min flumazenil injection and rapidly dissipated thereafter. The magnitude of these effects was comparable after 7, 14, and 28 days of diazepam. Flumazenil also produced modest elevations in blood pressure and decreases in skin temperature in the diazepam group, both of which were sustained throughout the approximate 60-min session.

Conclusions

These findings support previous human research studies indicating that flumazenil precipitates withdrawal after short chronic exposure to benzodiazepines and suggests that duration of exposure does not influence the intensity of withdrawal beyond the first week of exposure.

References

  1. Bernik MA, Gorenstein C, Gentil V (1991) Flumazenil-precipitated withdrawal symptoms in chronic users of therapeutic doses of diazepam. J Psychopharmacol 5:215–219Google Scholar
  2. Bernik MA, Gorenstein C, Vieira Filho AH (1998) Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users. J Psychopharmacol 12:146–150PubMedGoogle Scholar
  3. Brogden RN, Goa KL (1991) Flumazenil. A reappraisal of its pharmacodynamic properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs 42:1061–1089PubMedGoogle Scholar
  4. Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, Keller MB (2003) Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 160:1432–1438CrossRefPubMedGoogle Scholar
  5. Busto UE, Sykora K, Sellers, EM (1989) A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol 9:412–416PubMedGoogle Scholar
  6. Frey JM, Rush CR, Griffiths RR (1996) Physiological, behavioral and subjective effects of flumazenil-precipitated withdrawal in benzodiazepine-dependent methadone clients. Poster presented at the annual meeting of the Society for Neuroscience, Washington, DCGoogle Scholar
  7. Gallager DW, Heninger K, Heninger G (1986) Periodic benzodiazepine antagonist administration prevents benzodiazepine withdrawal symptoms in primates. Eur J Pharmacol 132:31–38CrossRefPubMedGoogle Scholar
  8. Gerra G, Marcato A, Caccavari R, Fertonani-Affini G, Fontanesi B, Zaimovic A, Avanzini P, Delsignore R (1993) Effectiveness of flumazenil (RO 15-1788) in the treatment of benzodiazepine withdrawal. Curr Ther Res Clin Exp 54:580–587Google Scholar
  9. Gerra G, Giucasto G, Zaimovic A, Fertonani G, Chittolini B, Avanzini P, Caccavari R, Delsignore R (1996) Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal. Int Clin Psychopharmacol 11:81–88PubMedGoogle Scholar
  10. Greenblatt DJ, Laughren TP, Allen MD, Harmatz JS, Shader RI (1981) Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy. Br J Clin Pharmacol 1:35–40Google Scholar
  11. Griffiths RR, Weerts EM (1997) Benzodiazepine self-administration in humans and laboratory animals-implications for problems of long-term use and abuse. Psychopharmacology (Berl) 134:1–37CrossRefGoogle Scholar
  12. Griffiths RR, Evans SM, Guarino JJ, Roache JD, Furman WR, Liebson I, Schwam EM (1993) Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: antagonism and precipitated withdrawal. J Pharmacol Exp Ther 265:1163–1174PubMedGoogle Scholar
  13. Harrison-Read PE, Tyrer P, Lawson C, Lack S, Fernandes C, File SE (1996) Flumazenil-precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. J Psychopharmacol 10:89–97Google Scholar
  14. Kaminski BJ, Sannerud CA, Weerts EM, Lamb RJ, Griffiths RR (2003) Physical dependence in baboons chronically treated with low and high doses of diazepam. Behav Pharmacol 14:331–342PubMedGoogle Scholar
  15. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337–344CrossRefPubMedGoogle Scholar
  16. Keppel G (1991) Design and analysis: a researcher’s handbook, 3rd edn. Prentice Hall, Englewood CliffsGoogle Scholar
  17. Lader MH, Morton SV (1992) A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. J Psychopharmacol 6:357–363Google Scholar
  18. Lamb RJ, Griffiths RR (1985) Effects of repeated Ro 15-1788 administration in benzodiazepine-dependent baboons. Eur J Pharmacol 110:257–261CrossRefPubMedGoogle Scholar
  19. Lamb RJ, Griffiths RR (1987) Effects of Ro 15-1788 and CGS 8216 in diazepam-dependent baboons. Eur J Pharmacol 143:205–212CrossRefPubMedGoogle Scholar
  20. Lukas SE, Griffiths RR (1982) Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15-1788) after 7 days of diazepam. Science 217:1161–1163PubMedGoogle Scholar
  21. Lukas SE, Griffiths RR (1984) Precipitated diazepam withdrawal in baboons: effects of dose and duration of exposure. Eur J Pharmacol 100:163–171CrossRefPubMedGoogle Scholar
  22. Martin WR, Sloan JW, Wala E (1990) Precipitated abstinence in orally dosed benzodiazepine-dependent dogs. J Pharmacol Exp Ther 255:744–755PubMedGoogle Scholar
  23. McNicholas LF, Martin WR (1982) The effect of a benzodiazepine antagonist, RO15-1788, in diazepam dependent rats. Life Sci 31:731–737CrossRefPubMedGoogle Scholar
  24. McNicholas LF, Martin WR, Sloan JW, Wala E (1988) Precipitation of abstinence in nordiazepam- and diazepam-dependent dogs. J Pharmacol Exp Ther 245:221–224PubMedGoogle Scholar
  25. Mintzer MZ, Stoller KB, Griffiths RR (1999) A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. Psychopharmacology 147:200–209CrossRefPubMedGoogle Scholar
  26. Nutt DJ (1990) Pharmacological mechanisms of benzodiazepine withdrawal. J Psychiatr Res 24(Suppl 2):105–110CrossRefPubMedGoogle Scholar
  27. Nutt DJ, Glue P, Lawson C, Wilson S (1990) Flumazenil provocation of panic attacks. Arch Gen Psychiatry 47:917–925PubMedGoogle Scholar
  28. Petursson H, Lader M (1984) Dependence on tranquilizers, Maudsley monographs 28. Oxford University Press, OxfordGoogle Scholar
  29. Physicians’ Desk Reference (2003) 57th edn. Medical Economics, MontvaleGoogle Scholar
  30. Rosenberg HC, Chiu TH (1985) Time course for development of benzodiazepine tolerance and physical dependence. Neurosci Biobehav Rev 9:123–131CrossRefPubMedGoogle Scholar
  31. Sannerud CA, Cook JM, Griffiths RR (1989) Behavioral differentiation of benzodiazepine ligands after repeated administration in baboons. Eur J Pharmacol 167:333–343CrossRefPubMedGoogle Scholar
  32. Sannerud CA, Allen M, Cook JM, Griffiths RR (1991) Behavioral effects of benzodiazepine ligands in non-dependent, diazepam-dependent and diazepam-withdrawn baboons. Eur J Pharmacol 202:159–169CrossRefPubMedGoogle Scholar
  33. Savic I, Widen L, Stone-Elander S (1991) Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet 337:133–137CrossRefPubMedGoogle Scholar
  34. Saxon L, Hjemdahl P, Hiltunen AJ, Borg S (1997) Effects of flumazenil in the treatment of benzodiazepine withdrawal—a double-blind pilot study. Psychopharmacology (Berl) 131:153–160CrossRefGoogle Scholar
  35. Scherkl R, Frey HH (1986) Physical dependence on clonazepam in dogs. Pharmacology 32:18–24PubMedGoogle Scholar
  36. Sloan JW, Martin WR, Wala E (1991a) Duration of diazepam (DZ) treatment and the intensity of flumazenil precipitated abstinence (FPA) in dogs. FASEB J 5:A703Google Scholar
  37. Sloan JW, Martin WR, Wala E, Dickey KM (1991b) Chronic administration of and dependence on halazepam, diazepam, and nordiazepam in the dog. Drug Alcohol Depend 28:249–264CrossRefPubMedGoogle Scholar
  38. Sloan JW, Martin WR, Wala E (1993) Effect of the chronic dose of diazepam on the intensity and characteristics of the precipitated abstinence syndrome in the dog. J Pharmacol Exp Ther 265:1152–1162PubMedGoogle Scholar
  39. Spielberger CD, Gorsuch RL, Lushene RE (1970) STAI manual for the state-trait anxiety inventory (“Self-Evaluation Questionnaire”). Consulting Psychologists, Palo AltoGoogle Scholar
  40. Wilson MA, Gallager DW (1988) Ro 15-1788-induced seizures in rats continually exposed to diazepam for prolonged periods. Epilepsy Res 2:14–19CrossRefPubMedGoogle Scholar
  41. Woods JH, Katz JL, Winger G (1987) Abuse liability of benzodiazepines. Pharmacol Rev 39:251–419PubMedGoogle Scholar
  42. Woods JH, Katz JL, Winger G (1992) Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 44:151–347PubMedGoogle Scholar
  43. Zharkovskii AM, Zharkovskaia TA (1987) Characteristics of the abstinence syndrome induced by the administration of the benzodiazepine antagonist CGS 8216 to rats following chronic treatment with diazepam. Biull Eksp Biol Med 104:318–321PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations